Products - Metastases | Topic | NICE

Showing 202 products

Date | Title

Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 February 2019
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
27 July 2016
Published:
27 June 2012
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
27 July 2016
Published:
27 April 2016
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 August 2021
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 April 2014
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 March 2014
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 August 2025
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 October 2021
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 May 2018
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2018
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 October 2021
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 June 2019
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor TSID 11812
Status:
Topic selection
Programme:
Health technology evaluation
Expected publication date:
TBC
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 July 2020
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) (TA730)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 September 2021
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy (TA788)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 May 2022
Avelumab for treating metastatic Merkel cell carcinoma (TA517)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
21 April 2021
Published:
11 April 2018
Avelumab for untreated metastatic Merkel cell carcinoma (TA691)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 April 2021
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 September 2020
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 January 2012
Published:
24 January 2007
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 August 2009
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 February 2011
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 August 2012
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 December 2010
Brain tumours (primary) and brain metastases in over 16s (NG99)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
29 January 2021
Published:
11 July 2018
Brain tumours (primary) and brain metastases in over 16s (QS203)
Product type:
Quality standard
Published:
7 December 2021
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
24 August 2016
Published:
25 May 2016
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency ID 6466
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Caris Molecular Intelligence for guiding cancer treatment (MIB120)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
20 September 2017
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 June 2023
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) (TA848)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 December 2022
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
30 April 2025
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
25 September 2017
Published:
29 March 2017
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 January 2012
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 August 2017
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 October 2016
Cryotherapy for the treatment of liver metastases (IPG369)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
15 December 2010
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 October 2014
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 October 2012
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 June 2006
EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
14 August 2013
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6225]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
5 February 2025
Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (IPG446)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 March 2013
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 January 2021
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
23 July 2025
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 February 2019
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) (TA797)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 June 2022
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Product type:
Guidance
Programme:
Technology appraisal guidance
Expected publication date:
15 June 2022
Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
4 June 2025
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 August 2020
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 July 2014
Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 July 2021
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 January 2016
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 February 2025
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 March 2018
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 December 2016
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 June 2012
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 June 2017
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fruquintinib for previously treated metastatic colorectal cancer ID6274
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
5 March 2025
Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2011
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 January 2018
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 July 2010
Gemcitabine for the treatment of metastatic breast cancer (TA116)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 January 2007
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 May 2003
High intensity focused ultrasound ablation for pain caused by bone metastases
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 November 2010
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 November 2010
Published:
27 October 2004
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer ID6425
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
7 August 2013
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 December 2012
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 July 2014
Irreversible electroporation for treating liver metastases (IPG445)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 February 2013
Irreversible electroporation for treating primary lung cancer and metastases in the lung (IPG441)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 February 2013
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (TA257)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 June 2012
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lifileucel for previously treated unresectable or metastatic melanoma ID3863
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 August 2018
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (TA930)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 November 2023
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver (IPG691)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
21 April 2021
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
26 April 2023
Published:
26 July 2010
Microwave ablation for primary or metastatic cancer in the lung (IPG716)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
2 February 2022
Microwave ablation for treating liver metastases (IPG553)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 April 2016
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 July 2015
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer TSID 12044
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA684)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 March 2021
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 July 2021
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 February 2016
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 July 2018
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 July 2016
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 February 2024
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 February 2023
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (TA724)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 September 2021
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 July 2021
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) (TA750)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 December 2021
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 May 2023
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) (TA762)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 February 2024
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 October 2020
OSNA for colon cancer staging (MIB77)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
24 August 2016
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 September 2017
Padeliporfin for untreated localised prostate cancer (TA546)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 November 2018
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 December 2017
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
29 March 2017
Published:
14 December 2011
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 April 2017
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
12 September 2017
Published:
25 November 2015
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 April 2021
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 March 2019
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 June 2021
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 November 2020
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) (TA674)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 February 2021
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 July 2018
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 June 2022
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA939)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 December 2023
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 February 2022
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TS ID 11810
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TS ID 12096]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 June 2023
Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA683)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 March 2021
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (TA983)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 June 2024
Percutaneous cementoplasty for palliative treatment of bony malignancies (IPG179)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 June 2006
Percutaneous cryotherapy (PCT) for the therapy of primary lung cancer or metastatic lung cancer
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 March 2018
Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer (MIB137)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
18 January 2018
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases (IPG759)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
5 April 2023
Radiofrequency ablation for colorectal liver metastases (IPG327)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
16 December 2009
Radiofrequency ablation for palliation of painful spinal metastases (IPG758)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
5 April 2023
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases ID6512
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 August 2016
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) (TA635)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 June 2020
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 February 2015
Regorafenib for previously treated metastatic colorectal cancer (TA866)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 February 2023
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 November 2017
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 December 2017
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver (IPG786)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
16 May 2024
Selective internal radiation therapy for unresectable colorectal metastases in the liver (IPG672)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
4 March 2020
Selective internal radiation therapy for unresectable colorectal metastases in the liver
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 March 2022
Spinal metastases and metastatic spinal cord compression (NG234)
Product type:
Guidance
Programme:
NICE guideline
Published:
6 September 2023
Spinal metastases and metastatic spinal cord compression (QS56)
Product type:
Quality standard
Last updated:
6 September 2023
Published:
27 February 2014
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 March 2009
Suspected cancer (QS124)
Product type:
Quality standard
Last updated:
5 December 2017
Published:
30 June 2016
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 February 2024
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
15 January 2025
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation ID 6460
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 June 2016
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 July 2024
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TA976)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 May 2024
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (TA862)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 February 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 September 2025
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (TA704)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 May 2021
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) (TA879)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 April 2023
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 November 2010
Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 August 2016
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments (TA852)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2022
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (TA1008)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 September 2024
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (TA786)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 April 2022
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 January 2015
Published:
12 December 2012
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 January 2013
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer TSID 12040
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC